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Background: Endocrine therapy (ET)–resistant ABC is dependent on cyclin dependent
kinase (CDK) 4/6. In the prospective, randomized, double-blind, phase 3 PALOMA-3
study, the CDK4/6 inhibitor PAL in combination with FUL significantly improved pro-
gression-free survival (PFS) vs placebo (PBO)þFUL (median PFS, 11.2 vs 4.6mo; abso-
lute difference, 6.6mo; hazard ratio [HR] 0.50 [95% CI, 0.40–0.62]; P< 0.000001).
Here, we report OS analysis with amedian follow up of 44.8mo.
Methods:HRþ/HER2– ABC (N¼ 521) patients (pts) who had relapsed or progressed
on prior ET were randomized 2:1 to PAL (125mg/d orally, schedule 3/1)þ FUL
(500mg per standard of care) or PBOþFUL. Primary endpoint was investigator-
assessed PFS. A key secondary endpoint was OS. OS analysis occurred when approxi-
mately 60% (n310) of the 521 pts died.
Results:Median OS improved with PALþFUL vs PBOþFUL by an absolute difference
of 6.9mo (Table). In pts with sensitivity to prior ET, the absolute improvement in
median OS was 10.0mo with PALþFUL vs PBOþFUL. In pts without visceral disease,
median OS significantly improved with PALþFUL vs PBOþFUL (11.5mo). Time to
end of the next-line treatment was 18.8 (PALþFUL) and 14.1 (PBOþFUL) mo (HR
0.68 [95%CI, 0.56–0.84]; P< 0.0001). Improvements in median OS, although not stat-
istically significant at the prespecified level, were shown with PALþFUL vs PBOþFUL
regardless of ESR1mutation status or prior lines of therapy. Median time on subse-
quent therapy was similar in both arms; median time to chemotherapy was 17.5
(PALþFUL) and 8.8 (PBOþFUL)mo (HR 0.58; P< 0.000001). No new safety signals
were observed with longer follow-up.
Conclusions: In HRþ/HER2– ABC pts, PALþFUL showed a clinically meaningful
improvement in OS (6.9mo vs PBOþFUL), especially in pts with sensitivity to prior
ET. The absolute difference of PFS gain was maintained in OS.
Clinical trial identification:NCT01942135.
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Table: LBA2_PR OS in the ITT population and by subgroup
Subgroup n (%) HR (95% CI) PALþFUL median
OS (95% CI)
PBOþFUL median
OS (95% CI)
1-sided
P value
Interaction
P value
ITT, stratified 521 (100) 0.81 (0.64–1.03) 34.9 (28.8–40.0) 28.0 (23.6–34.6) 0.043 –
ITT, unstratified 521 (100) 0.79 (0.63–1.00) 34.9 (28.8–40.0) 28.0 (23.6–34.6) 0.025
Sensitivity to previous endocrine therapy
Endocrine sensitive 410 (78.7) 0.72 (0.55–0.94) 39.7 (34.8–45.7) 29.7 (23.8–37.9) – 0.124
Endocrine resistant 111 (21.3) 1.14 (0.71–1.84) 20.2 (17.2–26.4) 26.2 (17.5–31.8) –
Site of metastatic disease
Visceral disease 311 (59.7) 0.85 (0.64–1.13) 27.6 (24.4–31.2) 24.7 (20.8–31.8) – 0.442
Nonvisceral disease 210 (40.3) 0.69 (0.46–1.04) 46.9 (39.3–NE) 35.4 (24.6–NE) –
Menopausal status at study entry
Postmenopausal 413 (79.3) 0.73 (0.57–0.95) 34.8 (28.8–40.1) 27.1 (22.8–32.1) – 0.251
Pre/perimenopausal 108 (20.7) 1.07 (0.61–1.86) 38.0 (24.4–NE) 38.0 (22.2–NE) –
FUL¼fulvestrant; HR¼hazard ratio; ITT¼intent-to-treat; NE¼not estimable; OS¼overall survival; PAL¼palbociclib; PBO¼placebo.
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